A Phase 1b trial of prexasertib in combination with chemoradiation in patients with locally advanced head and neck squamous cell carcinoma
Yang, Eddy S., Deutsch, Eric, Mehmet, Altan, Fayette, Jerome, TAO, Yungan, Nabell, Lisle, Spencer, Sharon A., Wang, Xuejing A., Spoljoric, Elizabeth A., Zhang, Wei, Hynes, Scott M., Decker, Rodney L., Lin, Aimee K. Bence, William, William N.
Published in Radiotherapy and oncology (01.04.2021)
Published in Radiotherapy and oncology (01.04.2021)
Get full text
Journal Article
Relative Bioavailability of Omaveloxolone When Capsules Are Sprinkled Over and Mixed in Applesauce Compared With Administration as Intact Omaveloxolone Capsules: A Phase 1, Randomized, Open‐Label, Single‐Dose, Crossover Study in Healthy Adults
Hynes, Scott M., Goldsberry, Angie, Henneghan, Patrick D., Murai, Masako, Shinde, Aparna, Wells, Jason A., Wu, Lucy, Wu, Tony, Zahir, Hamim, Khan, Seemi
Published in Journal of clinical pharmacology (01.10.2024)
Published in Journal of clinical pharmacology (01.10.2024)
Get full text
Journal Article
A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer
Patnaik, Amita, Gordon, Michael, Tsai, Frank, Papadopoulous, Kyri, Rasco, Drew, Beeram, S. Muralidhar, Fu, Siqing, Janku, Filip, Hynes, Scott M., Gundala, Sushma R., Willard, Melinda D., Zhang, Wei, Lin, Aimee Bence, Hong, David
Published in Cancer chemotherapy and pharmacology (01.09.2018)
Published in Cancer chemotherapy and pharmacology (01.09.2018)
Get full text
Journal Article
Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer
Scagliotti, Giorgio, Kang, Jin Hyoung, Smith, David, Rosenberg, Richard, Park, Keunchil, Kim, Sang-We, Su, Wu-Chou, Boyd, Thomas E., Richards, Donald A., Novello, Silvia, Hynes, Scott M., Myrand, Scott P., Lin, Ji, Smyth, Emily Nash, Wijayawardana, Sameera, Lin, Aimee Bence, Pinder-Schenck, Mary
Published in Investigational new drugs (01.10.2016)
Published in Investigational new drugs (01.10.2016)
Get full text
Journal Article
A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancer
Wehler, Thomas, Thomas, Michael, Schumann, Christian, Bosch-Barrera, Joaquim, Viñolas Segarra, Nuria, Dickgreber, Nicolas J, Dalhoff, Klaus, Sebastian, Martin, Corral Jaime, Jesus, Alonso, Miriam, Hynes, Scott M, Lin, Ji, Hurt, Karla, Bence Lin, Aimee, Calvo, Emiliano, Paz-Ares, Luis
Published in Lung cancer (Amsterdam, Netherlands) (01.06.2017)
Published in Lung cancer (Amsterdam, Netherlands) (01.06.2017)
Get full text
Journal Article
Understanding the mechanisms of food effect on omaveloxolone pharmacokinetics through physiologically based biopharmaceutics modeling
Pepin, Xavier J H, Hynes, Scott M, Zahir, Hamim, Walker, Deborah, Semmens, Lois Q, Suarez-Sharp, Sandra
Published in CPT: pharmacometrics and systems pharmacology (02.09.2024)
Published in CPT: pharmacometrics and systems pharmacology (02.09.2024)
Get full text
Journal Article
Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors
Doi, Toshihiko, Yoshino, Takayuki, Shitara, Kohei, Matsubara, Nobuaki, Fuse, Nozomu, Naito, Yoichi, Uenaka, Kazunori, Nakamura, Takashi, Hynes, Scott M, Lin, Aimee Bence
Published in Anti-cancer drugs (01.11.2015)
Published in Anti-cancer drugs (01.11.2015)
Get more information
Journal Article
Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer
Infante, Jeffrey R., Patnaik, Amita, Verschraegen, Claire F., Olszanski, Anthony J., Shaheen, Montaser, Burris, Howard A., Tolcher, Anthony W., Papadopoulos, Kyriakos P., Beeram, Muralidhar, Hynes, Scott M., Leohr, Jennifer, Lin, Aimee Bence, Li, Lily Q., McGlothlin, Anna, Farrington, Daphne L., Westin, Eric H., Cohen, Roger B.
Published in Cancer chemotherapy and pharmacology (01.02.2017)
Published in Cancer chemotherapy and pharmacology (01.02.2017)
Get full text
Journal Article
Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer
Calvo, Emiliano, Chen, Victor J., Marshall, Mark, Ohnmacht, Ute, Hynes, Scott M., Kumm, Elizabeth, Diaz, H. Bruce, Barnard, Darlene, Merzoug, Farhana F., Huber, Lysiane, Kays, Lisa, Iversen, Philip, Calles, Antonio, Voss, Beatrice, Lin, Aimee Bence, Dickgreber, Nicolas, Wehler, Thomas, Sebastian, Martin
Published in Investigational new drugs (01.10.2014)
Published in Investigational new drugs (01.10.2014)
Get full text
Journal Article
Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors
Calvo, Emiliano, Braiteh, Fadi, Von Hoff, Daniel, McWilliams, Robert, Becerra, Carlos, Galsky, Matthew D, Jameson, Gayle, Lin, Ji, McKane, Scott, Wickremsinhe, Enaksha R, Hynes, Scott M, Bence Lin, Aimee, Hurt, Karla, Richards, Donald
Published in Oncology (01.01.2016)
Published in Oncology (01.01.2016)
Get more information
Journal Article
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer
Weiss, Glen J, Donehower, Ross C, Iyengar, Tara, Ramanathan, Ramesh K, Lewandowski, Karen, Westin, Eric, Hurt, Karla, Hynes, Scott M, Anthony, Stephen P, McKane, Scott
Published in Investigational new drugs (01.02.2013)
Published in Investigational new drugs (01.02.2013)
Get full text
Journal Article
Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer
Patnaik, Amita, Gordon, Michael, Tsai, Frank, Papadopoulos, Kyriakos P., Rasco, Drew, Beeram, Muralidhar, Fu, Siqing, Janku, Filip, Hynes, Scott M., Gundala, Sushma R., Willard, Melinda D., Zhang, Wei, Lin, Aimee Bence, Hong, David
Published in Cancer chemotherapy and pharmacology (01.09.2018)
Published in Cancer chemotherapy and pharmacology (01.09.2018)
Get full text
Journal Article
Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patients
Hynes, Scott M., Wickremsinhe, Enaksha, Zhang, Wei, Decker, Rodney, Ott, Jennifer, Chandler, Jason, Mitchell, Malcolm
Published in Biopharmaceutics & drug disposition (01.01.2015)
Published in Biopharmaceutics & drug disposition (01.01.2015)
Get full text
Journal Article
Disposition and metabolism of LY2603618, a Chk-1 inhibitor following intravenous administration in patients with advanced and/or metastatic solid tumors
Wickremsinhe, Enaksha R., Hynes, Scott M., Palmieri, Margo D., Mitchell, Malcolm I., Abraham, Trent L., Rehmel, Jessica Fayer, Chana, Emilie, Jost, Lorenz M., Cassidy, Kenneth C.
Published in Xenobiotica (01.09.2014)
Published in Xenobiotica (01.09.2014)
Get full text
Journal Article
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer
Weiss, Glen J., Donehower, Ross C., Iyengar, Tara, Ramanathan, Ramesh K., Lewandowski, Karen, Westin, Eric, Hurt, Karla, Hynes, Scott M., Anthony, Stephen P., McKane, Scott
Published in Investigational new drugs (01.02.2013)
Published in Investigational new drugs (01.02.2013)
Get full text
Journal Article
Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer
Hong, David, Infante, Jeffrey, Janku, Filip, Jones, Suzanne, Nguyen, Ly M, Burris, Howard, Naing, Aung, Bauer, Todd M, Piha-Paul, Sarina, Johnson, Faye M, Kurzrock, Razelle, Golden, Lisa, Hynes, Scott, Lin, Ji, Lin, Aimee Bence, Bendell, Johanna
Published in Journal of clinical oncology (20.05.2016)
Published in Journal of clinical oncology (20.05.2016)
Get full text
Journal Article
A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients
Laquente, Berta, Lopez-Martin, Jose, Richards, Donald, Illerhaus, Gerald, Chang, David Z, Kim, George, Stella, Philip, Richel, Dirk, Szcylik, Cezary, Cascinu, Stefano, Frassineti, G L, Ciuleanu, Tudor, Hurt, Karla, Hynes, Scott, Lin, Ji, Lin, Aimee Bence, Von Hoff, Daniel, Calvo, Emiliano
Published in BMC cancer (15.02.2017)
Published in BMC cancer (15.02.2017)
Get full text
Journal Article
A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer
Byers, Lauren Averett, Navarro, Alejandro, Schaefer, Eric, Johnson, Melissa, Özgüroğlu, Mustafa, Han, Ji-Youn, Bondarenko, Igor, Cicin, Irfan, Dragnev, Konstantin H., Abel, Adam, Wang, Xuejing, McNeely, Samuel, Hynes, Scott, Lin, Aimee Bence, Forster, Martin
Published in Clinical lung cancer (01.11.2021)
Published in Clinical lung cancer (01.11.2021)
Get full text
Journal Article